The muscle-loss question has been hanging over the GLP-1 space since day one. Scale weight going down is easy to celebrate; the MRI data saying some of that is lean mass has always been the awkward footnote. On October 1, Regeneron posted Phase 2 results from the COURAGE trial that give the first serious answer to whether that loss can be pharmacologically blocked.
The compound is trevogrumab, an antibody against myostatin - the protein that puts the brakes on muscle growth. Block it, and the theory goes, your body holds onto muscle even while GLP-1s are melting fat off you.
What the Research Says
The data Regeneron announced on October 1 come from the lower-dose portion of COURAGE, which tested trevogrumab at 25 mg or 75 mg alongside semaglutide 2.4 mg for 52 weeks in adults with BMI of 30 or higher. COURAGE enrolled 975 people overall, 376 in this one-year portion, average age 49, 64% women. The full paper is in press with The Lancet.
Headline results:
- At 75 mg, lean mass fell 4.2% over 52 weeks versus 7.3% on semaglutide plus placebo - about 42% less lean mass loss, a statistically significant 3.1 percentage point difference
- The 25 mg dose cut lean mass loss by 1.5 percentage points (about 20%), which did not reach statistical significance
- In the MRI substudy of 76 participants, thigh muscle volume loss was 69% to 72% smaller with either trevogrumab dose than with semaglutide alone
- Adverse events ran slightly lower on the active arm (77% vs 82% placebo), with the usual GLP-1 GI symptoms most common
The Number That Matters More Than the Headline
The 42% figure is the headline, but the MRI substudy is the more interesting read. Total lean mass includes everything - water, organ mass, skin - and it is a blunt instrument. Thigh muscle volume is a direct measurement of actual skeletal muscle, and a 70% reduction in its loss suggests the mechanism is doing what myostatin blockade is supposed to do: protecting contractile tissue specifically.
Two caveats from the same release deserve airtime. First, trevogrumab did not meaningfully boost the weight loss itself - this is a body-composition intervention, not a fat-loss enhancer. Second, the dose-response went the “wrong” way in one sense: only the 75 mg dose hit statistical significance, so the therapeutic window question is open.
Why This Is a Big Deal for the GLP-1 Conversation
Roughly 25 to 40% of total weight lost on GLP-1 monotherapy can come from lean mass, depending on the trial and measurement method. For a compound class heading toward hundreds of millions of users, that is a population-scale body composition shift with unknown long-term consequences, particularly in older adults where muscle loss compounds sarcopenia risk.
That is exactly where Regeneron is heading next: a new Phase 2 testing trevogrumab with GLP-1s in older adults with obesity and reduced muscle mass or strength. No approval timeline has been given, and pricing and coverage are unknown.
There is a community angle here too. Muscle-preservation stacking - resistance training plus protein plus various “research” compounds - is one of the most discussed topics anywhere GLP-1 users gather. Trevogrumab is the first clinical-stage molecule with year-long Phase 2 data showing a pharmacological route to the same goal. It is also, importantly, not available anywhere outside trials: it has not been evaluated or approved by any regulator, and grey-market claims about “myostatin inhibitors” should be read against the fact that the real thing is still in Phase 2.
Our semaglutide page covers the base compound and its trial history, and the body composition discussion regularly comes up in the Grey Highway Telegram group.
The Fine Print
Phase 2, one year, one sponsor reporting its own trial. The Lancet paper is in press, not published, so the full tables are not public yet. The 25 mg arm missing significance while 75 mg hit it means dose optimisation is unfinished business. And lean mass preservation over 52 weeks says nothing about what happens after people stop - Regeneron has no published follow-up data on whether muscle regains normal kinetics post-treatment.
Still, as proof of concept goes, this is the cleanest demonstration yet that GLP-1 muscle loss is a tractable drug problem rather than an unavoidable tax on the class.
Sources
- Regeneron press release, October 1, 2026: Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass Loss
- Medical Daily, October 2026: Trevogrumab cut lean mass loss by about 42% over one year
- News-Medical trial summary, October 1, 2026: Trevogrumab cuts semaglutide-induced lean mass loss by half
- Medical Daily, Phase 2 bimagrumab context: Lean mass Phase 2 trial coverage
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.